These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10930890)

  • 41. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
    Hong EJ; Park DI; Oh SJ; Song MJ; Choi WH; Hong CH; Park JH; Kim HJ; Cho YK; Shon CI; Jeon WK; Kim BI
    Korean J Gastroenterol; 2008 Aug; 52(2):80-5. PubMed ID: 19077498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Proton pump inhibitors in developmental period medicine].
    Czerwionka-Szaflarska M; Brazowski J
    Pol Merkur Lekarski; 2007 Feb; 22(128):154-8. PubMed ID: 17598663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
    Miwa H; Ohkura R; Murai T; Sato K; Nagahara A; Hirai S; Watanabe S; Sato N
    Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
    Ogoshi K; Kato T; Sakagawa T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S97-9. PubMed ID: 7594354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
    Katoh M; Asaka M; Kudoh M; Kagaya H; Katagiri M; Takeda H
    J Clin Gastroenterol; 1995; 20 Suppl 2():S112-4. PubMed ID: 7594324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of lansoprazole on peptic ulcers.
    Ohashi T; Sakata J; Haraguchi Y; Eto T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S83-5. PubMed ID: 7594350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical efficacy of pantoprazole compared with ranitidine.
    Bader JP; Delchier JC
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():47-52. PubMed ID: 8180294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rabeprazole.
    Prakash A; Faulds D
    Drugs; 1998 Feb; 55(2):261-7; discussion 268. PubMed ID: 9506245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
    Johnson D; Perdomo C; Barth J; Jokubaitis L
    Eur J Gastroenterol Hepatol; 2000 Jul; 12(7):799-806. PubMed ID: 10929909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
    Javid G; Zargar SA; U-Saif R; Khan BA; Yatoo GN; Shah AH; Gulzar GM; Sodhi JS; Khan MA
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1236-43. PubMed ID: 19682194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton pump inhibitors: an update.
    Vanderhoff BT; Tahboub RM
    Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eradication of Helicobacter pylori infection.
    Hunt RH
    Am J Med; 1996 May; 100(5A):42S-50S; discussion 50S-51S. PubMed ID: 8644782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
    Harris AW; Misiewicz JJ; Bardhan KD; Levi S; O'Morain C; Cooper BT; Kerr GD; Dixon MF; Langworthy H; Piper D
    Aliment Pharmacol Ther; 1998 Aug; 12(8):741-5. PubMed ID: 9726387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.